AstraZeneca to acquire French drugmaker Amolyt Pharma for $1.05bn
AstraZeneca said that the acquisition will further expand the pipeline of Alexion, AstraZeneca Rare Disease, beyond complement inhibition,…
We use them to give you the best experience. If you continue using our website, we'll assume that you are happy to receive all cookies on this website.
ContinueLearn More X
15 Mar 24
AstraZeneca said that the acquisition will further expand the pipeline of Alexion, AstraZeneca Rare Disease, beyond complement inhibition,…
PharmaceuticalsActive Pharmaceutical Ingredients and Intermediates
11 Mar 24
The data from FRONTIER 2, the long-term extension to Phase 2b FRONTIER 1 study, showed that JNJ-2113 resulted…
PharmaceuticalsActive Pharmaceutical Ingredients and Intermediates
05 Mar 24
Acoramidis is an investigational, next-generation, orally administered, highly potent and selective small molecule transthyretin (TTR) stabiliser, intended for…
PharmaceuticalsActive Pharmaceutical Ingredients and Intermediates
13 Feb 24
Through the acquisition, Gilead will add Seladelpar, an investigational, oral, selective peroxisome proliferator-activated receptor delta (PPARδ) agonist intended…
PharmaceuticalsActive Pharmaceutical Ingredients and Intermediates
09 Feb 24
BioNTech and Autolus signed a license and option agreement to advance their individual autologous CAR-T programs towards commercialisation…
PharmaceuticalsActive Pharmaceutical Ingredients and Intermediates
31 Jan 24
Under the agreement, Regeneron will buy full development and commercialisation rights of 2seventy’s pipeline of investigational immune cell…
PharmaceuticalsActive Pharmaceutical Ingredients and Intermediates
31 Jan 24
The funds will be used to advance the development of Cour’s Myasthenia Gravis and Type 1 Diabetes product…
PharmaceuticalsActive Pharmaceutical Ingredients and Intermediates
30 Jan 24
Gilead has also made a $320m equity investment in Arcus and appointed its chief commercial officer Johanna Mercier…
PharmaceuticalsActive Pharmaceutical Ingredients and Intermediates
30 Jan 24
Through the acquisition, Roche gains access to Carmot's comprehensive research and development (R&D) portfolio, encompassing both clinical and…
PharmaceuticalsActive Pharmaceutical Ingredients and Intermediates
30 Jan 24
Synthekine to receive $40 million upfront payment and eligible to receive milestones, in addition to tiered royalties on…
PharmaceuticalsActive Pharmaceutical Ingredients and Intermediates